111 related articles for article (PubMed ID: 6765062)
1. [Bromocriptine in the treatment of Parkinson's disease].
Sepcić J; Ledić P
Neurologija; 1982; 30(1-4):75-81. PubMed ID: 6765062
[No Abstract] [Full Text] [Related]
2. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
3. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
[TBL] [Abstract][Full Text] [Related]
5. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
7. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Parkinson's disease with bromocriptine].
Castaigne P; Laplane D; Bousser MG; Bories F
Nouv Presse Med; 1976 Apr; 6(17):1482. PubMed ID: 1037400
[No Abstract] [Full Text] [Related]
9. [Bromocriptine in Parkinson's disease. Personal experience].
Chacón JR; Piqueras L; Pery JM
Arch Neurobiol (Madr); 1982; 45(5):371-80. PubMed ID: 7165448
[No Abstract] [Full Text] [Related]
10. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
11. [Bromocriptine and Parkinson's disease: initial results].
Petit H; Destee A
Lille Med; 1977; 22(6):362-5. PubMed ID: 578286
[No Abstract] [Full Text] [Related]
12. Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
Godwin-Austen RB
Adv Biochem Psychopharmacol; 1980; 23():261-5. PubMed ID: 7395616
[No Abstract] [Full Text] [Related]
13. A comparative study of bromocriptine and levodopa in Parkinson's disease.
Duvoisin RC; Mendoza MM; Yahr MD
Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
[No Abstract] [Full Text] [Related]
14. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
16. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
17. The role of bromocriptine in the treatment of Parkinson's disease.
Stern GM; Lees AJ; Shaw KM; Lander CM
Adv Biochem Psychopharmacol; 1980; 23():267-70. PubMed ID: 7395617
[No Abstract] [Full Text] [Related]
18. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
[TBL] [Abstract][Full Text] [Related]
19. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
Stern GM; Lees AJ
Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
[TBL] [Abstract][Full Text] [Related]
20. Patients sought for New Zealand multi-centre Parkinson's disease trial.
Wallis WE
N Z Med J; 1987 Jan; 100(816):33. PubMed ID: 3543760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
